Supplementary Figure S1 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
Steffan T. Nawrocki(University of Arizona), Kevin R. Kelly(Keck Hospital of USC), Paul Fields(Adaptive Biotechnologies (United States)), Jennifer S. Carew(University of Arizona), Kaijin Wu(University of Southern California), Eduardo Fernandez Hernandez(University of Southern California), Imran Siddiqi(University of Southern California), Julian Olea(University of Southern California), Claudia Villa Celi(University of Southern California), Denice Tsao‐Wei(Children's Hospital of Los Angeles), Gerard J. Nuovo(Life Sciences Discovery Fund), Akil Merchant(University of Southern California), Matt Coffey(Oncolytics Biotech (Canada)), Ann Mohrbacher(University of Southern California), Homa Dadrastoussi(University of Southern California), Peter Kühn(University of Southern California), Xuelian Chen(Jiangsu University), Anthony Colombo(Cedars-Sinai Medical Center)
Cited by 0
Related Papers
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
|Cancer Letters|2008|426
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
|Clinical Cancer Research|2015|355